HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $70
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Disc Medicine (NASDAQ:IRON) and raises the price target from $66 to $70.
August 14, 2023 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Disc Medicine and raises the price target from $66 to $70.
The news directly pertains to Disc Medicine (IRON) as the analyst from HC Wainwright & Co. maintains a Buy rating and raises the price target. This is likely to have a positive impact on the stock price in the short term as it indicates the analyst's positive outlook on the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100